17 April 2013 -- Nanosonics Limited (ASX: NAN) has today announced it has signed an agreement with Toshiba Medical Systems (Toshiba) to be a non-exclusive distributor of trophon® EPR in the United Kingdom.
Chief Executive Officer Dr Ron Weinberger said Toshiba will launch Nanosonics’ first-in-class ultrasound probe disinfection technology in April 2013, coinciding with the new UK fiscal year. Nanosonics will continue to sell directly into the UK market.
“We see trophon EPR as complementary to the Toshiba range of ultrasound machines, and as playing an important role in reducing infection control risk across the healthcare system. Toshiba looks forward to working with Nanosonics in the roll out of this important technology” Mark Hitchman, General Manager of Toshiba Medical Systems, UK, stated.
“We are delighted to be working with Toshiba, a rapidly growing leader in the UK ultrasound market. The health and safety benefits offered by the trophon EPR have attracted strong interest by both sonographers and decontamination professionals throughout the UK. Nanosonics’ direct operations in the UK have seen growth in the demand for product presentation and information from a broad range of healthcare professionals. This strategic engagement with Toshiba will give trophon EPR greater exposure within this market and facilitate adoption of trophon EPR as the Standard of Care in probe decontamination” Dr Weinberger said.
“We estimate that the UK opportunity for trophon EPR is likely to be significant in light of the recent regulatory drivers. It is early days yet and it will take time to build sales volume. However, the signs are encouraging that the UK operations will make an important contribution to global sales revenue” Dr Weinberger commented.
For more information please contact:
Ron Weinberger, CEO or McGregor Grant, CFO, on 02 8063 1600
Kyahn Williamson, Media Relations, Buchan Consulting on (03) 9866 4722
